|
|
Article: Dynavax Reports New TOLAMBA Data at ACAAI Meeting.
- Article from:
- PR Newswire
- Article date:
- November 12, 2006
CopyrightCOPYRIGHT 2006 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
New Analysis Confirms TOLAMBA Benefits Entire Ragweed Allergy Patient Population; Confirms Mechanism of Action
BERKELEY, Calif., Nov. 12 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation today reported additional data from a Phase 2b study showing TOLAMBA(TM), the company's novel ragweed investigational therapy, benefited treated patients, regardless of the severity of their disease. In a presentation at the annual meeting of the American College of Allergy, Asthma and Immunology (ACAAI) in Philadelphia, Dynavax explained that the data extends the company's understanding of the clinical benefit of the drug candidate as well its mechanism of action.
...